|Calculated MW||29231 Da|
|Application & Usage||The peptide is used for blocking the antibody activity of Calsenilin. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30 minutes at 37°C.|
|Other Names||Calsenilin, A-type potassium channel modulatory protein 3, DRE-antagonist modulator, DREAM, Kv channel-interacting protein 3, KChIP3, KCNIP3, CSEN, DREAM, KCHIP3|
|Formulation||50 µg (0.2 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 0.1% BSA and 0.02% sodium azide.|
|Reconstitution & Storage||-20 °C|
|Precautions||Calsenilin Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CSEN, DREAM, KCHIP3|
|Function||Calcium-dependent transcriptional repressor that binds to the DRE element of genes including PDYN and FOS. Affinity for DNA is reduced upon binding to calcium and enhanced by binding to magnesium. Seems to be involved in nociception (By similarity).|
|Cellular Location||Cytoplasm. Cell membrane; Lipid-anchor Endoplasmic reticulum. Golgi apparatus. Nucleus. Note=Also membrane-bound, associated with the plasma membrane (PubMed:15485870). In the presence of PSEN2 associated with the endoplasmic reticulum and Golgi. The sumoylated form is present only in the nucleus|
|Tissue Location||Highly expressed in brain. Widely expressed at lower levels. Expression levels are elevated in brain cortex regions affected by Alzheimer disease|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.